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The insulin-like growth factor-binding proteins (IGFBPs) are evolutionarily conserved compo-
nents of the insulin-like growth factor (IGF) system. The six forms of IGFBPs (IGFBP-1–6)
bind the IGF ligands (IGF-1 and -2) with high affinity and regulate the IGFs available to their
receptors, therefore providing additional flexibilities in regulating IGF signalling. IGFBP-1, the
first identified member of the IGFBP family is highly inducible under a variety of catabolic
conditions, such as food deprivation, malnutrition, stress, injury and hypoxia. Recent in vivo
studies have indicated that the induced IGFBP-1 serves as a molecular switch by restricting IGF
signalling and diverts the limited energy resources away from growth and development towards
those metabolic processes essential for survival. This article reviews the recent understandings of
the molecular basis of IGFBP-1 regulation and its biological functions, as revealed through
research in mammalian and fish models. # 2007 The Authors
Journal compilation # 2007 The Fisheries Society of the British Isles
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ROLES OF INSULIN-LIKE GROWTH FACTOR-BINDING
PROTEINS IN CONTROLLING IGF ACTIONS
Insulin-like growth factors (IGF-1 and -2) have been established as key mole-
cules that regulate a variety of cellular processes including proliferation, differ-
entiation, survival and migration. The special importance of IGF signalling in
embryonic development is demonstrated by studies showing that targeting
disruption of the IGF-1, IGF-2 and/or IGF-1 receptor gene in mice or natural
mutations in human patients results in severe dwarfism (DeChiara et al., 1990;
Baker et al., 1993; Liu et al., 1993; Woods et al., 1996; Abuzzahab et al., 2003;
Dupont & Holzenberger, 2003). The biological actions of IGFs are mainly medi-
ated through type-1 (IGF-1) receptor on the cell surface, leading to tyrosine
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phosphorylation of the beta-domain of the receptor and subsequent signalling
cascades such as the mitogen-activated protein kinase (MAPK), phosphoinosi-
tol-3-kinase and protein kinase B (Akt) signalling pathways (Le Roith et al.,
2001; Nakae et al., 2001). In contrast, the type-2 IGF receptor, identified as
the cation-independent mannose-6-phosphate receptor, lacks recognizable cata-
lytic domains and presumably works for clearance of IGF-2 (Braulke, 1999).
The molecular interactions of IGFs with their receptor are tightly regulated
by six distinct forms of IGF-binding proteins (IGFBPs), referred to as IGFBP-1
through IGFBP-6. IGFBPs are secreted proteins with molecular masses of
24–44 kDa that share highly conserved N-terminal and C-terminal domains
and a variable linker (L)-domain. Since IGFBPs bind IGFs with greater affin-
ities (KD c. 01 nM) than IGF receptors (KD c. 1 nM), over 95% of IGFs in
extracellular fluids form complexes with IGFBPs. In addition, the majority
of IGFBP-3 and -5 in the circulation are associated with a glycoprotein known
as acid-labile subunit to form 130–150 kDa of ternary complex. It has been
considered that the roles of the IGF/IGFBP complex are (1) to prevent poten-
tial hypoglycemia resulting from cross-activation of the insulin receptor, (2) to
mediate the efflux of IGFs from the vascular space to the cell surface and (3) to
prolong their half-lives in circulation by inhibiting proteolytic degradation
(Clemmons, 2001; Duan, 2002; Firth & Baxter, 2002; Duan & Xu, 2005).
Importantly, these IGFBPs provide an additional level (temporal and spatial)
of flexibility for co-ordinating the delivery of ‘biologically active’ IGFs to spe-
cific target cells. Despite the fact that the six IGFBPs share structural homol-
ogy, each IGFBP has distinct characteristics and plays different roles in
controlling IGF signalling, depending on the physiological context and the cell
types (Fig. 1). For example, IGFBP-3 and -5 have a heparin-binding motif that
binds to the glycosaminoglycan side chains and other components in the extra-
cellular matrix (ECM). The binding of the IGF/IGFBP complex to the ECM
reduces the affinity of the IGF–IGFBP interaction, causing release and deliver-
ing of free IGFs to the target cells. Thus, these IGFBPs potentiate the IGF
actions (enhancing effect). In contrast, several IGFBPs, including IGFBP-1,
inhibit IGF-1 activity by competing for the same binding surface of IGF-1 with
IGF-1R (Jansson et al., 1998). Proteolysis of IGFBP-1 by the IGFBP protease
decreases the binding affinity; therefore, the released IGFs are able to interact
and activate IGF-1R (inhibitory effect). In addition, a new mode of IGFBP
action, i.e. ligand-independent effect, has been reported. Despite the fact that
all the IGFBPs are secreted proteins, IGFBP-3 and -5 are localized in the
nucleus through their nuclear localization signal in the C-domain (Firth &
Baxter, 2002; Xu et al., 2004). The nuclear localized IGFBP-3 has been re-
ported to interact with the retinoid-X receptor a and that interaction is impor-
tant for the IGFBP-3-induced apoptosis in prostate cancer cells (Liu et al.,
2000). More recently, IGFBP-3 has been reported to interact with RNA poly-
merase II binding subunit 3, implying its possible involvement in gene tran-
scription (Oufattole et al., 2006). A recent study has also shown that the
nuclear IGFBP-5 is in a complex containing histone H3 and that the N-domain
of both IGFBP-3 and -5 possess transactivation activity in a ligand-independent
manner (Zhao et al., 2006). Therefore, the IGFBPs also provide the novel inter-
face with the transcription machinery independent from the ligands binding, in
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addition to their conventional functions as IGF modulators. For comprehensive
reviews on the structure perspectives of the IGFBP family, readers are referred
to several recent reviews (Clemmons, 2001; Firth & Baxter, 2002; Duan & Xu,
2005). For a comparative overview of IGFBPs, see two review articles by
Kelley et al. (2002) and Wood et al. (2005).
STRUCTURAL AND BIOCHEMICAL FEATURES OF IGFBP-1
IGFBP-1, the authors focus in this review, is the first identified member of
the IGFBP family, initially purified from human amniotic fluid (Drop et al.,
1984a, b, also see review by Lee et al., 1997). Human IGFBP-1 consists of
234 amino acids with 12 cysteine residues in the N-domain and 6 cysteine res-
idues in the C-domain [Fig. 2(a)]. Both the N- and the C-domains of IGFBP-1
directly interact with IGF-1 but not with insulin, and the L-domain acts as
a hinge. The L-domain is rich in proline, glutamate, serine and threonine
(PEST), known to increase the susceptibility to proteolysis. The instability of
IGFBP-1 through the PEST sequence allows quick turnover (Lee et al.,
1997). Another characteristic motif of IGFBP-1 is the Arg–Gly–Asp (RGD)
sequence in the C-domain. It has been demonstrated that IGFBP-1 binds via
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FIG. 1. The insulin-like growth factor (IGF) system. Two IGF ligands (IGF-1 and -2), two receptors
(IGF-1 receptor and type-2 IGF receptor) and six forms of IGF-binding proteins (IGFBPs) are
shown. IGFBP-3 and -5 form ternary complexes with acid-labile subunits (ALS) that stabilize the
IGFBP/IGF complex in circulation. Three modes of IGFBP action are proposed: (1) enhancing
effects of IGF actions, (2) inhibitory effects of IGF actions and (3) ligand-independent action. See
text for detail. ECM, extracellular matrix.
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the RGD motif to a5b1 integrin and stimulates cell migration (Jones et al.,
1993c). Since the C-domain of IGFBP-1 or IGFBP-1 without IGF-1-binding
ability is still able to stimulate cell migration, this effect is considered to be
ligand independent (Jones et al., 1993c; Sala et al., 2005). The interaction of
IGFBP-1 with a5b1 integrin leads to the activation of focal adhesion kinase
dephosphorylation, and consequently, induces cell detachment and apoptotic
cell death in human breast cancer cells (Perks et al., 1999).
Several studies have reported the post-translational modifications of IGFBP-1
including polymerization and phosphorylation that affect its function (Busby
et al., 1989; Sakai et al., 2001). According to Sakai et al. (2001), IGFBP-1 forms
multimers upon the stimulus of transglutaminase type 2. Non-phosphorylated
IGFBP-1 polymerizes more rapidly and to a greater extent, leading to the
attenuation of the IGFBP-1’s inhibitory effects on IGF-1-stimulated protein
synthesis. However, phosphorylation at Ser101, Ser119 and Ser169 of human
IGFBP-1 enhances the binding affinity to IGF-1 by six-fold (Jones et al.,
1991, 1993a, b). Gibson et al. (2001) have reported that placental alkaline phos-
phatase, presumably produced in trophoblast, dephosphorylates the phosphor-
ylated forms of IGFBP-1. Since the non-phosphorylated form is more
susceptible to the proteolysis degradation, the phosphatase is able to regulate
the availability of IGFs by controlling the amount of local IGFBP-1 through
post-translational modifications. In addition, the relationship between IGFBP-1










FIG. 2. Structural and biochemical features of IGFBP-1. (a) Structure of human IGFBP-1 (234 amino
acids). It can be divided into three domains, i.e. the amino-terminal domain (N-domain) containing
12 cysteine residues, the linker domain (L-domain) and the carboxyl-terminal domain (C-domain)
containing 6 cysteine residues. The proline, glutamate, serine and threonine (PEST) sequence in the
L-domain and the Arg–Gly–Asp (RGD) motif in the C-domain are shown. Three phosphorylation
sites are indicated. (b) Structure of the zebrafish IGFBP-1 gene. It spans 5 kb in the genome,
composed of four exons and three introns. Note that all the 18 cysteine residues are located in
conserved position with mammalian counterparts; however, the PEST, RGD motifs and phosphor-
ylation sites are not conserved.
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phosphorylation and pathological condition has been suggested (Frost et al.,
1994; Westwood et al., 1994; Gibson et al., 1999). However, unlike human
IGFBP-1, rat IGFBP-1 phosphorylated at Ser107 and Ser132 retains its
affinity to IGF-1 regardless of the phosphorylation status (Peterkofsky et al.,
1998).
In teleosts, it has been known that the serum from several species contains at
least three major IGFBPs around 20–25, 30 and 40–45 kDa (Kelley et al., 1992,
2001; Anderson et al., 1993; Fukazawa et al., 1995; Siharath et al., 1996;
Shimizu et al., 1999, 2000; Park et al., 2000; Kajimura et al., 2003; Riley et al.,
2004; Davis & Peterson, 2006; see also the reviews by Kelley et al., 2002 and
Wood et al., 2005). Based on the molecular sizes and the hormonal regulations
of mammalian counterparts, one of the IGFBPs under 30 kDa was speculated
to be fish IGFBP-1 (Kelley et al., 1992, 2001, 2002; Siharath et al., 1996;
Shimizu et al., 1999, 2000; Park et al., 2000; Bauchat et al., 2001; Kajimura
et al., 2003; Riley et al., 2004; Peterson & Small, 2005; Shepherd et al.,
2005). Bauchat et al. (2001) purified a 30 kDa IGFBP from the cultured rain-
bow trout liver cells. Based on the structural homology and biochemical prop-
erties, this IGFBP is the trout homologue of human IGFBP-1. Shimizu et al.
(2005) purified a 22 kDa IGFBP from Chinook salmon serum and character-
ized it as IGFBP-1. To date, the full-length IGFBP-1 sequence has been re-
ported for zebrafish (Maures & Duan, 2002), rainbow trout (Kamangar et al.,
2006) and a partial sequence for longjaw mudsucker (Gracey et al., 2001). The
zebrafish IGFBP-1 gene spans 5 kb in the genome (Kajimura et al., 2005). It
is composed of four exons and three introns located in a tail-to-tail position
with the IGFBP-3 gene, as reported in mammals [Fig. 2(b)]. Although fish
IGFBP-1 shows the highest homology to human IGF-1 among the IGFBP
family, the actual identity is modest (36–40%), perhaps due to the low homol-
ogy in the L-domain (15–20%). Fish IGFBP-1 also shares significant sequence
identity to human IGFBP-4 (34–39%). Its identities with other human IGFBPs
are substantially lower. All the 18 cysteine residues are located in conserved po-
sitions in fish IGFBP-1; however, the PEST and RGD motifs are not found.
Furthermore, none of the phosphorylation sites, identified in human and rat,
are conserved in fish IGFBP-1. Consistent with the structural features of
fish IGFBP-1, it has been shown that fish IGFBP-1 by itself had no effects
on the cell proliferation of zebrafish embryonic cells (Bauchat et al., 2001;
Kajimura et al., 2005).
REGULATION OF IGFBP-1
From earlier studies that measure IGFBP-1 levels in a number of physiolog-
ical conditions, it has been revealed that circulating IGFBP-1 displays dynamic
kinetics. The rapid and highly inducible profile distinguishes IGFBP-1 from
other IGFBPs. The half-life of IGFBP-1 in circulation is estimated in the range
of 7–13 min (Lee et al., 1997). In addition to the protein instability through the
PEST sequence, the instability of mRNA contributes to the high turnover of
IGFBP-1. The 39-untranslated region (39-UTR) of IGFBP-1 mRNA contains
multiple ‘ATTTA’ sequences, known to play a role in transiently expressed
mRNAs (Gay & Babajko, 2000).
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Circulating IGFBP-1 levels are greatly influenced by nutritional status and
insulin levels, implying their involvement in glucose metabolism. In fact, insulin
is one of the major endocrine regulators of IGFBP-1 transcription. The pro-
moter region of the mammalian IGFBP-1 gene contains a palindrome sequence
of insulin response elements [IRE: T(G/A)TTT(T/G)(T/G)] that mediate the
inhibitory effects of insulin (Suwanickul et al., 1993). A forkhead transcription
factor family, named hepatic nuclear factor-3, was initially shown to bind to the
IRE (Unterman et al., 1994; Allander et al., 1997). However, subsequent studies
have demonstrated that the forkhead box O1 (FoxO1) (previously described as
FKHR) is the bona fide protein that binds to the IRE in the human IGFBP-1
gene and mediates the insulin effects (Durham et al., 1999; Nakae et al., 2006).
Glucocorticoid is another potent endocrine regulator of IGFBP-1expression.
Glucocorticoid induces IGFBP-1 at the transcription level, although insulin acts
in a dominant manner to suppress basal- and glucocorticoid-induced IGFBP-1
expression (Suwanichkul et al., 1994; O’Brien et al., 1995). The biological effect
of glucocorticoid is mediated through the direct binding of the glucocorticoid
receptor (GR) to the GR response elements (GRE) on the human IGFBP-1
promoter, located contiguous to the IREs (Goswami et al., 1994; Gan et al.,
2005). It should be noted that, FoxO proteins also act cooperatively to mediate
the glucocorticoid-induced IGFBP-1 expression through recruiting cAMP
response element-binding protein /p300 and the steroid receptor coactivator
complex (Nasrin et al., 2000). Furthermore, several endocrine factors are re-
ported to regulate IGFBP-1 gene expression including glucagon (Kachra et al.,
1994), progesterone (Gao et al., 1994; Gao & Tseng, 1997), interleukin-6 (Leu
et al., 2001) and vitamin D (Matilainen et al., 2005). The cis-elements of these
factors are identified as cAMP response element (CRE), progesterone receptor
response element, hepatocyte nuclear factor-1-binding site and vitamin receptor
response element on the IGFBP-1 promoter region, respectively.
IGFBP-1 is also induced by a variety of catabolic conditions. For example,
fasting, malnutrition and protein restriction rapidly induce IGFBP-1 at the
transcription level (Busby et al., 1988; Ooi et al., 1990; Murphy et al., 1991;
Straus et al., 1993; Takenaka et al., 1993). Interestingly, depletion of a single
amino acid (arginine, cysteine and each of the essential amino acids) is suffi-
cient to induce IGFBP-1 expression in vitro (Jousse et al., 1998; Takenaka
et al., 2000). According to Takenaka et al. (2000), the promoter region contain-
ing both IRE and GRE on the rat IGFBP-1 gene is required for the IGFBP-1
induction in response to amino acid depletion. Averous et al. (2005) have
also reported that amino acid depletion stabilizes IGFBP-1 mRNA through
its 39-UTR region. Furthermore, Patel et al. (2002) have demonstrated that rapa-
mycin inhibits the mammalian target of rapamycin (mTOR), an essential inte-
grator of nutrient signalling, and abolishes the inhibitory effect of insulin on
IGFBP-1 expression. Since amino acid depletion per se downregulates the mTOR
signalling, the mTOR pathway through IRE appears to be involved in the
nutrition-dependent IGFBP-1 regulation in conjunction with the glucocorticoid-
mediated pathway. The underlying molecular mechanisms of how single amino
acid depletion regulates IGFBP-1 remain unclear at this time.
Other catabolic conditions regulating IGFBP-1 expression include endoplas-
mic reticulum (ER) stress and hypoxia. Under ER stress, unfolded proteins are
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accumulated within the cell, and the co-ordinated adaptive programmes are
triggered to alleviate ER stress through several proteins. One of them is activating
transcription factor-4 (ATF-4), a basic leucine zipper (bZIP) transcription factor
that regulates ER-induced gene expressions including CCAAT enhancer-binding
protein (C/EBP) homologous protein (Ohoka et al., 2005). Marchand et al.
(2006) have demonstrated that a distal regulatory region of human IGFBP-1
contains an ATF-4-binding site [(R/C)TT(R/T)CRTCA, R ¼ G/A] at 6481/
6473 to which ATF-4 specifically binds. Since mutation of the ATF-4-binding
site or knockdown of endogenous ATF-4 blunts the induction of IGFBP-1 by
ER stress, ATF-4 mediates the ER-stress-induced IGFBP-1 expression.
Another example is the regulation of IGFBP-1 expression in a hypoxic envi-
ronment. Hypoxia triggers the transcriptional changes in a number of genes
that promote O2 delivery and anaerobic respiration and suppress major
energy-requiring processes (Guillemin & Krasnow, 1997; Huang et al., 2004;
Seta & Millhorn, 2004). Many of these transcriptional responses to hypoxia
are mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric com-
plex composed of HIF-1a and aryl hydrocarbon receptor nuclear translocator.
HIF-1a is subjected to the constant degradation via ubiquitin and the proteo-
some pathway when oxygen levels are ample. In a hypoxic environment, how-
ever, HIF-1a is stabilized and eventually accumulates within the nucleus, where it
activates target gene expression by direct binding to the consensus cis-regulatory
DNA sequence, named hypoxia response element (HRE; A/G CGTG)
(Semenza, 1999; Bruick, 2003). Several in vitro and in vivo studies have shown
that IGFBP-1 is a hypoxia-inducible gene (McLellan et al., 1992; Tazuke et al.,
1998; Popovici et al., 2001). Furthermore, significantly higher levels of serum
IGFBP-1 are found at higher altitude (Krampl, 2002). Tazuke et al. (1998)
have identified a HRE located in intron 2 of the human IGFBP-1 gene respon-
sible for the hypoxia response in cultured human hepatoma cells. Likewise,
recent studies using zebrafish embryo show that the induction of IGFBP-1 gene
expression by hypoxia is mediated through HIF-1 both in vitro and in vivo, and
the HIF-1 pathway is established in early embryonic stages (Kajimura et al.,
2006). Although the zebrafish IGFBP-1 promoter contains 13 potential HREs
within a 21 kb region upstream of the translational start site, only one HRE
positioned at 1090/1086 is responsible for the hypoxia and HIF-1-induced
IGFBP-1 expression. Intriguingly, an additional cis-element, HIF-1 ancillary
sequence (HAS), is required for the responsiveness to hypoxia and to HIF-1
(Kajimura et al., 2006). Since HAS exists close to the authentic HRE site in
the IGFBP-1 gene of mammalian species as well as in other hypoxia-responsive
genes, including vascular endothelial growth factor, erythropoietin and lactate
dehydrogenase A, the requirement of HAS for the hypoxia responses may be
applicable not only to the IGFBP-1 gene but also to many, if not all, of the
hypoxia-inducible genes (Kimura et al., 2001; Kajimura et al., 2006). The iden-
tification and functional characterization of HAS awaits further investigation.
The hormonal regulation of IGFBP-1 gene expression appears to be con-
served between mammals and teleost species. IGFBP-1 or a lower molecular
weight (20–30 kDa) IGFBP is induced by fasting, stress, hypoxia and salinity
challenge (Siharath et al., 1996; Kelley et al., 2001, 2002; Kajimura et al., 2005,
2006; Shepherd et al., 2005; Davis & Peterson, 2006). In the cultured tilapia
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hepatocyte, oestradiol-17b and 5a-dihydrotestosterone have been found to reg-
ulate the release of IGFBP-1 (Riley et al., 2004). Moreover, cortisol or dexa-
methasone treatment increases circulating IGFBP-1 and its gene expression
(Kajimura et al., 2003; Peterson & Small, 2005; Pierce et al., 2006). Using a
homologous radioimmunoassay of salmon IGFBP-1, Shimizu et al. (2006) dem-
onstrated that circulating IGFBP-1 levels were inversely correlated with somatic
growth in Chinook salmon. Although the functional contribution remains
unclear, the promoter region of the IGFBP-1 gene in zebrafish contains multiple
hormonal regulatory cis-elements including GRE and CRE, as found in mam-
malian species, suggesting conserved mechanisms to regulate IGFBP-1 under
catabolic conditions. Pierce et al. (2006) have recently reported that insulin did
not have inhibitory effects on IGFBP-1 gene expression nor protein levels in
the salmon hepatocytes. The mechanisms underlying the lack of the inhibitory
effects by insulin are unknown. The identification of the authentic cis-elements
responsible for the hormonal/environmental stimuli is a future direction of study.
PHYSIOLOGICAL FUNCTIONS OF IGFBP-1
A number of in vitro studies have shown that IGFBP-1 has an inhibitory
effect on IGF activity. As described above, the inhibitory effects seem to be
mainly through competing for the same binding site in IGF-1 for IGF-1R. Sev-
eral in vivo models with gain of function approaches support this view. A trans-
genic mouse model expressing IGFBP-1 driven by the phosphoglycerokinase
promoter causes growth retardation and hyperglycaemia (Rajkumar et al., 1995).
Another transgenic mouse line under the control of a liver-specific promoter
(antitrypsin promoter) also displays pleiotropic defects in several skeletal units,
delayed mineralization, antenatal growth retardation and reproduction defects
(Gay et al., 1997; Froment et al., 2002; Ben Lagha et al., 2006). Crossey et al.
(2002) established a transgenic line using its own promoter that mimics the
endogenous expression in foetal liver and decidual tissue. These mice show foetal
growth retardation in midgestation and defects in placental development. Since
the excess amounts of IGFBP-1 in amniotic fluid impaired foetal growth regard-
less of the foetal genotype, maternal IGFBP-1 causes the placental insufficiency.
However, Watson et al. (2006) employed an a-foetoprotein gene promoter that
directs the IGFBP-1 expression predominantly in the foetal liver without altering
the circulating IGF-1 levels or nutrient supply to the foetus. These mice display
foetal growth retardation resembling the intrauterine growth restriction pheno-
type. In zebrafish embryos, overexpression of IGFBP-1 reduced the embryo size
to 83% of the control and also caused developmental delay (Kajimura et al.,
2005). Therefore, the high level of IGFBP-1 in the embryo is sufficient to induce
growth retardation. Overall, regardless of the difference in the amount, tissue
and timing of the transgene expression, these studies confirmed the importance
of IGFBP-1 in regulating embryonic growth through restricting IGF actions.
Although most studies report the inhibitory effects of IGFBP-1 on IGF activity,
several papers have shown the stimulatory effects of IGFs mitogenic action in
the presence of low concentrations of platelet-poor plasma in some cell lines.
It is speculated that IGF-1/IGFBP-1 complex sustains the release of IGF-1 to
receptor, leading to the potentiation of IGF-1 actions (Jones & Clemmons,
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1995). On the other hand, the loss-of-function approach in the mouse model does
not provide the definitive evidence for IGFBP-1 as a growth regulator.
IGFBP-1 knockout mice were normal in growth and development during
pre- and post-natal stages (Leu et al., 2003a, b). This appears to be due to
the compensatory effects by other IGFBPs that have redundancy in function
and expression patterns. Similar findings have been reported in other IGFBP
members. IGFBP-2 knockout mice also have minor phenotypic aside from
a smaller spleen and a larger liver (Wood et al., 2000). Knockout mice for
IGFBP-3, -5 and -6 have also been generated, but these animals appeared nor-
mal in size and shape (Pintar et al., 2001). Consistent with these findings, tran-
sient knockdown of IGFBP-1 by morpholino oligos did not cause any
developmental defects in zebrafish embryos. However, under certain stressful
conditions, loss of IGFBP-1 exhibits clear defects. IGFBP-1 null mice showed
impaired DNA synthetic response and liver necrosis during liver regeneration
after partial hepatoectomy, although liver mass restoration was normal (Leu
et al., 2003a). This impairment was associated with the reduced responses of
MAPK/extracellular signal-regulated kinase and C/EBP b that are involved
in the liver regeneration process. In addition, loss of IGFBP-1 leads to massive
apoptosis in the liver after treatment with a Fas ligand or liver injury, and
pretreatment with IGFBP-1 was able to rescue this abnormality (Leu et al.,
2003b). These results suggest that IGFBP-1 plays a critical role as a survival
factor. Since the liver expresses IGF-1R at a very low level, the effects on hepa-
tocyte cell proliferation may be IGF independent. A knock-in approach would
be necessary to test this notion using IGFBP-1 mutants that do not interact
with IGFs or mutants without the RGD sequence.
The loss of function approach has been successful in zebrafish embryos prob-
ably because of the lack of maternal compensation in gene knockout progeny
via placental circulation. Chronic hypoxia treatment results in significant
embryonic growth retardation and developmental delay, concomitant with a sig-
nificant increase in IGFBP-1 mRNA and protein levels. The targeted knock-
down of IGFBP-1 partially (43–65%) alleviated the hypoxia-caused growth
retardation and developmental delay. Reintroduction of an MO-resistant
IGFBP-1 to the IGFBP-1 knocked down embryos and restored the hypoxia
effects. Furthermore, the inhibitory effect of IGFBP-1 on IGF-dependent cell
proliferation was reversed in the presence of excess IGF-1 or IGF-2, whereas
IGFBP-1 per se did not have any effects (Kajimura et al., 2005). Therefore,
the mode of IGFBP-1 action is primarily through reducing free/active forms
of IGFs and the consequent suppression of IGF signalling (Fig. 3). These find-
ings provide strong evidence supporting the hypothesis that IGFBP-1 plays
a key role in hypoxia-caused growth retardation and developmental delay by
binding foetal IGF and inhibiting their growth-promoting activities.
In summary, there is compelling evidence that IGFBP-1 is a fine tuner of
IGF actions under a number of catabolic and stressful conditions. In the nor-
mal environment, the inhibition of IGF signalling by IGFBP-1 is in an ‘off’
mode, thus favouring fast growth and development. In a condition unfavourable
to growth and development, highly induced IGFBP-1 is ‘turned on’ to restrict
IGF signalling by binding free IGFs. This involvement of insulin/IGF signal-
ling in a catabolic environment has also been indicated in invertebrates. For
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example, it has been demonstrated in the nematode Caenorhabditis elegans that
the wild type does not survive in a hypoxic environment, whereas the daf-2
mutant (insulin receptor mutation) is highly tolerant to hypoxia, mediated
through an Akt-1/PDK-1/FKHR pathway overlapping with, but distinct from,
signalling pathways regulating life span (Scott et al., 2002). Because these
stressful and catabolic conditions lead to adaptive changes in metabolic reor-
ganization, such as the activation of the anaerobic ATP-generating pathway
(glycolysis), the biological significance of IGFBP-1 may be to serve as a molec-
ular switch by controlling the availability of IGFs to their receptors and to
divert the limited energy resources away from growth and development
towards those metabolic processes essential for survival.
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